709 related articles for article (PubMed ID: 33948911)
1. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.
Boinpally R; Spaventa J; Chen K; Butler M
Clin Drug Investig; 2021 Jun; 41(6):557-567. PubMed ID: 33948911
[TBL] [Abstract][Full Text] [Related]
2. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Boinpally R; Jakate A; Butler M; Periclou A
Pain Manag; 2022 May; 12(4):499-508. PubMed ID: 34898273
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R; McGeeney D; Borbridge L; Trugman J
Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
5. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
[TBL] [Abstract][Full Text] [Related]
6. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetic interactions and safety of atogepant coadministered with esomeprazole.
Boinpally R; Butler M; Rojo J; Borbridge L; Wangsadipura V; Papinska A
Pain Manag; 2023 Jun; 13(6):351-361. PubMed ID: 37424270
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate).
Rousseau FS; Wang L; Sprague TN; Lategan TW; Berkovich RR
Mult Scler Relat Disord; 2023 Feb; 70():104500. PubMed ID: 36645997
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants.
Wang L; Luan Y; Jia C; Xie X; Zhang Z; Xie X; Wang Q; Hu C; Xie F; Abdel-Moneim M; Hovsepian L; Zhao Z; Yang N; Hou J
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):51-62. PubMed ID: 36437383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]